RT Journal Article
SR Electronic
T1 CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 256
OP 259
DO 10.1136/jclinpath-2012-201020
VO 66
IS 3
A1 David J Pinato
A1 Paul Nya
A1 Rohini Sharma
A1 Francesco A Mauri
YR 2013
UL http://jcp.bmj.com/content/66/3/256.abstract
AB Background The differential diagnosis between malignant mesothelioma (MM) and metastatic lung adenocarcinoma (MLA) often relies on immunohistochemical studies, with no individual immunomarker holding satisfactory discrimination ability. Methods We investigated the diagnostic accuracy of CD24 immunoreactivity on 134 patients including 69 cases of MM and 65 MLA. Results The expression of CD24 favoured MLA, with 57/65 cases showing positive cytoplasmic staining compared with 9/69 MM (p<0.001), whose immunopositivity pattern was prevalently membranous (7/9 cases). Conclusions CD24 positivity can accurately discriminate MM from MLA. Prospective studies are warranted to clarify whether CD24 could integrate with other immunomarkers to facilitate the diagnosis of mesothelial malignancies.